Join Growin Stock Community!

Scinai immunotherapeutics ltd.SCNI.US Overview

US StockHealthcare
(No presentation for SCNI)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

SCNI AI Insights

SCNI Overall Performance

SCNI AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

SCNI Recent Performance

-

Scinai immunotherapeutics ltd.

0.05%

Avg of Sector

-0.31%

S&P500

SCNI PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

SCNI Key Information

SCNI Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

SCNI Profile

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.

Price of SCNI

SCNI FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

SCNI Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-6.06
PE Ratio (TTM)
0.22
Forward PE
-
PS Ratio (TTM)
2.47
PB Ratio
1.38
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-114.38%
Net Margin
-634.08%
Revenue Growth (YoY)
177.94%
Profit Growth (YoY)
-247.94%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-6.06
PE Ratio (TTM)
0.22
Forward PE
-
PS Ratio (TTM)
2.47
PB Ratio
1.38
Price-to-FCF
-
Gross Margin
-114.38%
Net Margin
-634.08%
Revenue Growth (YoY)
177.94%
Profit Growth (YoY)
-247.94%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is SCNI's latest earnings report released?

    The most recent financial report for Scinai immunotherapeutics ltd. (SCNI) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating SCNI's short-term business performance and financial health. For the latest updates on SCNI's earnings releases, visit this page regularly.

  • What is the operating profit of SCNI?

    According to the latest financial report, Scinai immunotherapeutics ltd. (SCNI) reported an Operating Profit of -963.49K with an Operating Margin of -347.46% this period, representing a growth of 60.19% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is SCNI's revenue growth?

    In the latest financial report, Scinai immunotherapeutics ltd. (SCNI) announced revenue of 277.29K, with a Year-Over-Year growth rate of 65.05%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does SCNI have?

    As of the end of the reporting period, Scinai immunotherapeutics ltd. (SCNI) had total debt of 2.36M, with a debt ratio of 0.2. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does SCNI have?

    At the end of the period, Scinai immunotherapeutics ltd. (SCNI) held Total Cash and Cash Equivalents of 1.13M, accounting for 0.1 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is SCNI's EPS continuing to grow?

    According to the past four quarterly reports, Scinai immunotherapeutics ltd. (SCNI)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -1.2. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of SCNI?

    Scinai immunotherapeutics ltd. (SCNI)'s Free Cash Flow (FCF) for the period is -1.29M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 26.67% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.